Navigation Links
Neurocrine Biosciences Reports First Quarter 2008 Results
Date:4/30/2008

er 31, 2007 of $276.7 million and $179.4 million, respectively. The Company expects to end 2008 with in excess of $100 million in cash and marketable securities.

"We have made significant strides in moving our GnRH program forward with three active Phase II clinical trials underway, a substantially complete preclinical package, as well as completing a commercial manufacturing and formulation process. To date we have treated approximately 500 subjects in our GnRH trials with elagolix. Elagolix has been generally safe and well tolerated with clinically meaningful reduction in endometriosis symptoms, such as dysmenorrhea, in most study participants. On the GnRH partnering front, we continue in collaboration discussions with multiple pharmaceutical companies. We will not speculate on a timeline for the completion of this deal," said Kevin Gorman, Ph.D., President and Chief Executive Officer of Neurocrine Biosciences. "Our goals for the GnRH program are to continue building value through our clinical trials and to secure the very best partner to fully develop this important asset. On the financial front, we continue to effectively manage our cash burn by prioritizing spending while advancing our pipeline."

R & D Pipeline Update

Neurocrine's clinical development group and corporate partners have five programs in clinical development and will report on R & D progress throughout 2008. Neurocrine scientists continue to supply Neurocrine's pipeline to meet the Company-wide goal of bringing one new compound into development each year.

GnRH Antagonists for endometriosis

Elagolix in Three Phase II Clinical Trials for Endometriosis

Below is a summary of the current ongoing randomized placebo controlled Phase II trials for elagolix:

Topline

Trial Study Design Endpoints n Status Results

0603 Six-month treatment 1. I
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
3. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
4. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
5. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
6. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
7. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
8. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
9. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
10. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
11. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Calif. , July 31, 2014 Lazarus ... of novel interventional devices to facilitate removal of blood ... Proceeds from the financing will support EU commercialization of ... filings for the Lazarus ReCover™ and Lazarus Cover™ in ... "This financing reflects investor confidence in the value of ...
(Date:7/31/2014)... VIENNA , July 31, 2014 ... New York results of AFF008, a ... disease. PD01A is the first therapy against the protein alpha-synuclein, ... The Michael J. Fox Foundation for Parkinson,s Research (MJFF) ... presented at the press conference on the impact a disease-modifying ...
(Date:7/31/2014)... , July 31, 2014 Astellas has ... of corporate and employee communications in the Americas ... Winton , senior vice president, chief communications officer. ... developing and leading corporate brand initiatives and reputation ... North and South America . ...
Breaking Medicine Technology:Lazarus Effect Closes $5 Million Financing 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2
... WORTH, Texas, Aug. 24, 2011 The UNT System Board ... authorized in the 82nd Texas legislative session. As part of ... and UNT Dallas, the College of Pharmacy students will earn ... graduate portion of their classes on the UNT Health Science ...
... Technologies, Inc. ( www.heartsine.com ), a world leader in ... the samaritan ® PAD 300P Public Access ... a school serving children and young people with intellectual ... (AED) is now available for Camphill staff enabling ...
Cached Medicine Technology:UNT Regents Approve New College of Pharmacy 2HeartSine® Technologies Donates Lifesaving AED to Camphill Special School 2
(Date:8/1/2014)... US (PRWEB) August 01, 2014 Get ... in partnership with PitchBook presents the 3Q 2014 Private ... U.S private equity investment, exits and fundraising activity in ... insight to help plan for private equity endeavors for ... registration form to download it now. , About Merrill ...
(Date:7/31/2014)... California (PRWEB) July 31, 2014 Serious ... Dead Psychedelic Acid Test concert posters. Owsley Bear Stanley, ... logo for the Grateful Dead. According to Hawley, “The ... to promote acid test parties in San Francisco and ... were printed on three different colors of paper. They ...
(Date:7/31/2014)... Atlanta, GA (PRWEB) July 31, 2014 ... construction camera on its Ponce City Market project ... the historic Sears, Roebuck & Company building into best-in-class ... nears completion, OxBlue reviewed Jamestown’s experience with their construction ... needs. , Jamestown wanted a construction camera ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 United Theological ... 9 a.m. on Monday, September 15, with its 2014 ... Church, 3440 Shroyer Rd., Kettering, OH. Dr. Emma ... in the Emma Toussant Chair will speak on “Unexpected ... Dr. Justes’ teaching and research interests include pastoral care ...
(Date:7/31/2014)... In today’s world, a good night’s sleep ... and sleep apnea (a medical problem where the airway collapses ... partners of the rest they need to face their daily ... and 20 million people in the United States alone have ... treated; and of those treated, many cannot tolerate their prescribed ...
Breaking Medicine News(10 mins):Health News:Register to Download Merrill DataSite's Report: PitchBook 3Q 2014 Private Equity Breakdown Report 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 3Health News:United Theological Seminary to Open 144th Year 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... News) -- Successful treatment of major depression in mothers also ... a new study. Children of parents with major depression ... This study included 80 women with depression and their ... a U.S. National Institute of Mental Health trial designed to ...
... Scientists have shown that an experimental vaccine against the human ... contagious nonbacterial illnesses that cause diarrhea and vomiting can ... cause the animals any harm. Using a novel viral ... shown promise in other agents designed to fight such infections ...
... the first laparoscopic procedure was performed to remove a ... St. Louis, this breakthrough minimally invasive technique has become ... achievement is celebrated with a series of cutting-edge articles ... published by Mary Ann Liebert, Inc. ( www.liebertpub.com ). ...
... considered a safe procedure, although complications can occur. The ... reports perforation rates of 0.03%-0.8% for diagnostic procedures, and ... perforation are the result of either mechanical disruption of ... a diverticulum, or stretching of the bowel with loops ...
... successfully treated for depression are at higher risk of losing ... study in the March 15, 2011 issue of the journal ... third of those who experience a stroke develop depression, a ... of health and rehabilitation sciences and of medicine at Indiana ...
... Ben-Gurion University of the Negev (BGU) researchers have shown that ... may have Obstructive Sleep Apnea (OSA), which may be the ... study compared men between the ages of 55 and 75 ... BPE and reported nocturia at least once nightly. The comparison ...
Cached Medicine News:Health News:New vaccine candidate shows strong potential to prevent highly contagious norovirus 2Health News:New vaccine candidate shows strong potential to prevent highly contagious norovirus 3Health News:New vaccine candidate shows strong potential to prevent highly contagious norovirus 4Health News:20th anniversary of first laparoscopic nephrectomy 2Health News:Managing post-stroke depression improves physical functioning 2Health News:Managing post-stroke depression improves physical functioning 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: